http://rdf.ncbi.nlm.nih.gov/pubchem/patent/HU-206091-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_76195fd1cd08192222699d8e7a88c231 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-535 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-04 |
| filingDate | 1987-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76734b11bc8b30094185d480aa2eea37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_442ab64d537b6968fc643bfccfd8decc |
| publicationDate | 1992-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | HU-206091-B |
| titleOfInvention | Process for producing 1,2,3,4-tetrahydro-6-substituted-4-aryl- or heterocyclic-3-/(substituted-amino)-carbonyl/-2-thioxo- or -oxo-5-pyrimidine carboxylic acids and their esters, as well as pharmaceutical compositions comprising such compounds |
| abstract | Cardiovascular activity is exhibited by compounds having the formulan and pharmaceutically acceptable salts thereof wherein X is oxygen or sulfur;n R is hydrogen, alkyl, cycloalkyl, aryl, or arylalkyl and R 1 is hydrogen, alkyl, cycloalkyl, aryl, heterocyclo,n or halo or halo substituted alkyl, or R and Ri taken together with the nitrogen atom to which they are attached are 1-pyrrolidinyl, 1-piperidinyl, 1-azepinyl, 4-morpholinyl, 4-thiamorpholinyl, 1-piperazinyl, 4-alkyl-1-piperazinyl, 4-arylalkyl-1-piperazinyl, 4-diarylalkyl-1-piperazinyl or 1-pyrrolidinyl, 1-piperidinyl, or 1-azeipinyl substituted with alkyl, alkoxy, alkylthio, halo, trifluoromethyl or hydroxy; R 2 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl,n or halo substituted or halo substituted alkyl; R 3 is hydrogen, alkyl, cycloalkyl, aryl, heterocyclo,n or halo or halo substituted alkyl; R 4 is aryl or heterocycto; Rs and R 6 are each independently hydrogen, alkyl, -(CH2)q-aryl or -(CH 2 ) q -cycloalkyl; Yi is cycloalkyl, aryl, heterocyclo, hydroxyl, alkoxy, aryl-(CH 2 ) m -O-, mercapto, alkylthio, aryl-(CH 2 ) m -S-, amino, substituted amino, carbamoyl, (n heterocy-n aryl-n Y 2 is cycloalkyf, aryl, heterocyclo, carbamoyl, (substitutedn alkoxycarbonyl,n orn Y 3 is hydroxyl, alkoxy, aryl-(CH2)m-O-, mercapto, alkylthio, aryl-(CH 2 )m-S-,n amino, or substituted amino; q is 0, 1, 2 or 3; m is 0 or an integer of 1 to 6; n is 0 or an integer of 1 to 5; and p is an integer of 1 to 5. |
| priorityDate | 1986-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 181.